Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Literature DB >> 33442537

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

Masatoshi Kudo¹.

Abstract

Entities: Disease Gene

Keywords: Atezolizumab; Bevacizumab; Combination immunotherapy; Immune checkpoint inhibitors

Year: 2020 PMID： 33442537 PMCID： PMC7768125 DOI： 10.1159/000512170

Source DB: PubMed Journal: Liver Cancer ISSN： 1664-5553 Impact factor: 11.740

× No keyword cloud information.

25 in total

1. Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2019-04-29 Impact factor: 11.740

2. Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2019-01-15 Impact factor: 11.740

3. Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.

Authors: Masatoshi Kudo
Journal: Liver Cancer Date: 2019-09-27 Impact factor: 11.740

4. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors: Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal: Lancet Oncol Date: 2018-06-03 Impact factor: 41.316

5. Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.

Authors: Naoshi Nishida; Kazuko Sakai; Masahiro Morita; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yoriaki Komeda; Mamoru Takenaka; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Kazuto Nishio; Masatoshi Kudo
Journal: Liver Cancer Date: 2020-03-17 Impact factor: 11.740

6. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Authors: Richard S Finn; Baek-Yeol Ryoo; Philippe Merle; Masatoshi Kudo; Mohamed Bouattour; Ho Yeong Lim; Valeriy Breder; Julien Edeline; Yee Chao; Sadahisa Ogasawara; Thomas Yau; Marcelo Garrido; Stephen L Chan; Jennifer Knox; Bruno Daniele; Scot W Ebbinghaus; Erluo Chen; Abby B Siegel; Andrew X Zhu; Ann-Lii Cheng
Journal: J Clin Oncol Date: 2019-12-02 Impact factor: 44.544

Review 7. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma.

Authors: Akihisa Ueno; Yohei Masugi; Ken Yamazaki; Yutaka Kurebayashi; Hanako Tsujikawa; Kathryn Effendi; Hidenori Ojima; Michiie Sakamoto
Journal: Pathol Int Date: 2020-01-06 Impact factor: 2.534

8. Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.

Authors: Roser Pinyol; Daniela Sia; Josep M Llovet
Journal: Clin Cancer Res Date: 2019-01-07 Impact factor: 12.531

Review 9. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

Authors: Masatoshi Kudo
Journal: Cancers (Basel) Date: 2020-04-27 Impact factor: 6.639

10. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.

Authors: Richard S Finn; Masafumi Ikeda; Andrew X Zhu; Max W Sung; Ari D Baron; Masatoshi Kudo; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; Konstantin Mamontov; Tim Meyer; Tomoki Kubota; Corina E Dutcus; Kenichi Saito; Abby B Siegel; Leonid Dubrovsky; Kalgi Mody; Josep M Llovet
Journal: J Clin Oncol Date: 2020-07-27 Impact factor: 44.544

7 in total

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.

1. Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

2. Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.

3. Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.

4. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

5. Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.

6. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Review 7. Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma.

8. Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.

Review 9. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

10. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.

1. Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

Review 2. Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Review 3. Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.

Review 4. Targets of immunotherapy for hepatocellular carcinoma: An update.

5. How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?

6. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.

7. Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?